Ractigen
1 known investors
Ractigen Therapeutics is a clinical-stage pharmaceutical company developing therapies based on RNA activation (RNAa), which uses small activating RNA (saRNA) to increase expression of targeted endogenous genes. Its pipeline addresses oncology, neurological and neuromuscular disorders, and liver-related indications, including monogenic and previously undruggable diseases.
BiotechHealthtech
Investors Β· 1
Frequently asked questions
- What does Ractigen do?
- Ractigen Therapeutics is a clinical-stage pharmaceutical company developing therapies based on RNA activation (RNAa), which uses small activating RNA (saRNA) to increase expression of targeted endogenous genes. Its pipeline addresses oncology, neurological and neuromuscular disorders, and liver-related indications, including monogenic and previously undruggable diseases.
- Who are Ractigen's investors?
- Ractigen's investors include Eisai Innovation, Inc..